Skip to main
GHRS
GHRS logo

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing innovative mebufotenin-based therapies for Treatment-Resistant Depression (TRD), including its proprietary product candidates GH001 and GH002. Recent positive results from a competitor's Phase 3 study in TRD therapies have highlighted a favorable market outlook for psychedelic treatments, which could enhance investor confidence in GH Research's profile and potential growth. Furthermore, the differentiated efficacy of GH001, characterized by its demonstrated magnitude of benefit, positions the company favorably within the competitive landscape, indicating strong prospects for future development and commercialization.

Bears say

GH Research PLC is facing significant financial challenges, as the company is expected to incur net losses until at least the approval and commercialization of its products, which may extend into the early launch phase. Additionally, the absence of granted patents or exclusive licenses for its mebufotenin therapies raises concerns about the company's intellectual property protection, potentially hindering its market competitiveness and pricing strategies. These issues, combined with ongoing legal and intellectual property risks, contribute to a negative outlook for the company's financial health and stock performance.

GHRS has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Strong Buy based on their latest research and market trends.

According to 8 analysts, GHRS has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.